evobrutinib (M2951) / EMD Serono 
Welcome,         Profile    Billing    Logout  
 5 Diseases   3 Trials   3 Trials   423 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
evobrutinib (M2951) / EMD Serono
EVOLUTION RMS1, NCT04338022 / 2019-004972-20: Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Terminated
3
1124
Europe, Canada, US, RoW
Teriflunomide, Evobrutinib, M2951
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
evolutionRMS 2, NCT04338061 / 2019-004980-36: Study of Evobrutinib in Participants With RMS

Terminated
3
1166
Europe, Canada, US, RoW
Teriflunomide, Evobrutinib, M2951
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
MS200527-0086, NCT02975349 / 2016-001448-21: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Terminated
2
267
Europe, RoW
Evobrutinib, M2951, Placebo, Tecfidera
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
01/18
04/24
NCT07215806: Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive

Completed
1
20
Europe
Evobruitnib, Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy
11/22
11/22
NCT07214935: A TQT Study of Effect of M2951 on Cardiac Repolarization

Completed
1
36
Europe
Placebo matched to M2951, Moxifloxacin, M2951 Low Dose, Evobrutinib, MSC2364447C, M2951 High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy
08/23
08/23
NCT07214922: Relative Bioavailability of Evobrutinib Tablet Batches

Completed
1
28
Europe
Treatment A, Evobrutinib, Treatment B, Treatment C, Treatment D
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy
02/23
02/23
MS200527_0091, NCT05245396: Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants

Completed
1
58
Europe
Ref (TF2), M2951, Evobrutinib MR-T1, Evobrutinib MR-T2, Evobrutinib MR-T3, Evobrutinib MR-T4, Evobrutinib MUPS-C1, Evobrutinib MUPS-C2, Evobrutinib MUPS-C3, Evobrutinib MUPS-C4, Evobrutinib MR-T adapated
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany
Healthy
02/23
02/23

Download Options